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Objectives: This study sought to evaluate the safety and
efficacy of rosuvastatin in preventing contrast-induced acute
kidney injury (CI-AKI) in patients with diabetes mellitus (DM)
and chronic kidney disease (CKD).
Background: CI-AKI is an important complication after
contrast medium injection. While small studies have shown
positive results with statin therapy, the role of statin therapy
in prevention of CI-AKI remains unknown.
Methods: We randomized 2998 patients with type 2 DM
and concomitant CKD who were undergoing coronary/pe-
ripheral arterial angiography with or without percutaneous
intervention to receive rosuvastatin, 10 mg/day (n ¼ 1498), for
5 days (2 days before, and 3 days after procedure) or standard-
of-care (n ¼ 1500). Patients' renal function was assessed at
baseline, 48 h, and 72 h after exposure to contrast medium.
The primary endpoint of the studywas the development of CI-
AKI, which was defined as an increase in serum creatinine
concentration 0.5 mg/dl (44.2 mmol/l) or 0.25% above base-
line at 72 h after exposure to contrast medium.
Results: Patients randomized to the rosuvastatin group had
a significantly lower incidence of CI-AKI than controls (2.3%
vs.3.9%, respectively; p ¼ 0.01). During 30 days' follow-up, the
rate of worsening heart failure was significantly lower in the
patients treated with rosuvastatin than that in the control
group (2.6% vs. 4.3%, respectively; p ¼ 0.02).
Conclusions: Rosuvastatin significantly reduced the risk of
CI-AKI in patients with DM and CKD undergoing arterial
contrast medium injection.1. Perspective
CI-AKI risk increases dramatically in patients with DMor CKD.
Besides these, other risk factors for CI-AKI are: 1) presentationas ACS 2) advanced NYHA Class 3) anaemia and 4) decreased
eGFR. Because these risk factors can be easily identified, pro-
phylactic measures for the prevention of CI-AKI should be
considered in these patients.
Present day strategies to prevent CI-AKI include: 1) intra-
venous hydration with saline 2) reduced use of contrast and
preferably an iso-osmolar agent like iodixanol and 3) N-acetyl
cysteine (NAC).
The present study is the first of its kind, which has evalu-
ated short-term (5 days) low dose rosuvastatin (10 mg/day)
started 2 days prior to angiography or PCI in patients with DM
and stage 2 or 3 CKD. The incidence of CI-AKI was significantly
lower in patients receiving rosuvastatin in comparison to
those receiving standard treatment strategies. 62.5 patients
would need to be treated to prevent one case of CI-AKI.
The strength of the present study is its large sample size
(3000 patients), all diabetics and with mild CKD. Rosuvastatin
prevents CI-AKI even in patients with normal lipid levels. The
most beneficial effect was seen in patients with stage 2 (mild
CKD).
Statins are known to exert pleiotropic effects and have
anti-inflammatory action via reduced hsCRP levels. The pre-
ventive effects of rosuvastatin on CI-AKI can be because of 1)
anti-inflammatory action 2) prevention of direct contrast
toxicity like apoptosis of renal cells.
In my opinion, identification of patients at risk of CI-AKI
and institution of measures like intravenous hydration and
use of low volume of contrast is of paramount importance.
Patients undergoing angiography and PCI anyway receive
statins. The present study only re-emphasizes this point. The
extra knowledge this study has added is that even in patients
with mild CKD, emphasis should be given to prevent CI-AKI
and low dose short duration statins are a newer addition to
the present day preventive measures for CI-AKI.
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